Velphoro sucroferric oxyhydroxide regulatory update

Galenica and its specialty pharma business, Vifor Pharma Ltd., said FDA approved an NDA for Velphoro sucroferric oxyhydroxide to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. Partner Fresenius' Fresenius Medical Care North America unit will launch the oral iron-based phosphate binder in the U.S. next year. ...